Cargando…

Anti-PD-1 Therapy—A Potential Treatment for Myocardial Metastasis From Nasopharyngeal Carcinoma: A Case Report

Myocardial metastasis of nasopharyngeal carcinoma (NPC) is rarely reported in the literature. Some autopsy studies found metastases in more than 10% of cases with malignant neoplasm. However, patients are often diagnosed during the postmortem because myocardial metastasis is often asymptomatic, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Xiaowan, Zhou, Weijun, Huang, Danjiang, Chen, Lili, Zhang, Guangwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602087/
https://www.ncbi.nlm.nih.gov/pubmed/34804001
http://dx.doi.org/10.3389/fimmu.2021.688682
_version_ 1784601502720983040
author Tang, Xiaowan
Zhou, Weijun
Huang, Danjiang
Chen, Lili
Zhang, Guangwen
author_facet Tang, Xiaowan
Zhou, Weijun
Huang, Danjiang
Chen, Lili
Zhang, Guangwen
author_sort Tang, Xiaowan
collection PubMed
description Myocardial metastasis of nasopharyngeal carcinoma (NPC) is rarely reported in the literature. Some autopsy studies found metastases in more than 10% of cases with malignant neoplasm. However, patients are often diagnosed during the postmortem because myocardial metastasis is often asymptomatic, and its Cardiac complications tend to be severe and fatal. Patients with Cardiac metastases are often treated with chemotherapy or surgical intervention, although the prognosis is poor. Immunotherapy with anti-programmed cell death receptor-1 or ligand-1 (PD-1 or PD-L1) inhibitors has recently been reported to be therapeutically significant in multiple cancers, including melanoma, nonsmall cell lung cancer, and NPC, but the treatment of myocardial metastasis of NPC has not been reported. This study described the case of a 50-year-old male patient who presented initially with NPC and received radiotherapy as first-line therapy. For 20 years, he had recurrent Cardiac metastasis of NPC. The pathological examination suggested tPD-L1 expression. Therefore, off-label sintilimab (200 mg every 21 days) was administered. After 10 cycles of treatment, myocardial metastasis shrank and the enlarged mediastinal lymph nodes disappeared. This case report demonstrated that Cardiac metastasis of NPC expressing PD-L1 might have a sustained response to PD-L1 inhibitor–directed therapy.
format Online
Article
Text
id pubmed-8602087
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86020872021-11-20 Anti-PD-1 Therapy—A Potential Treatment for Myocardial Metastasis From Nasopharyngeal Carcinoma: A Case Report Tang, Xiaowan Zhou, Weijun Huang, Danjiang Chen, Lili Zhang, Guangwen Front Immunol Immunology Myocardial metastasis of nasopharyngeal carcinoma (NPC) is rarely reported in the literature. Some autopsy studies found metastases in more than 10% of cases with malignant neoplasm. However, patients are often diagnosed during the postmortem because myocardial metastasis is often asymptomatic, and its Cardiac complications tend to be severe and fatal. Patients with Cardiac metastases are often treated with chemotherapy or surgical intervention, although the prognosis is poor. Immunotherapy with anti-programmed cell death receptor-1 or ligand-1 (PD-1 or PD-L1) inhibitors has recently been reported to be therapeutically significant in multiple cancers, including melanoma, nonsmall cell lung cancer, and NPC, but the treatment of myocardial metastasis of NPC has not been reported. This study described the case of a 50-year-old male patient who presented initially with NPC and received radiotherapy as first-line therapy. For 20 years, he had recurrent Cardiac metastasis of NPC. The pathological examination suggested tPD-L1 expression. Therefore, off-label sintilimab (200 mg every 21 days) was administered. After 10 cycles of treatment, myocardial metastasis shrank and the enlarged mediastinal lymph nodes disappeared. This case report demonstrated that Cardiac metastasis of NPC expressing PD-L1 might have a sustained response to PD-L1 inhibitor–directed therapy. Frontiers Media S.A. 2021-11-05 /pmc/articles/PMC8602087/ /pubmed/34804001 http://dx.doi.org/10.3389/fimmu.2021.688682 Text en Copyright © 2021 Tang, Zhou, Huang, Chen and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Tang, Xiaowan
Zhou, Weijun
Huang, Danjiang
Chen, Lili
Zhang, Guangwen
Anti-PD-1 Therapy—A Potential Treatment for Myocardial Metastasis From Nasopharyngeal Carcinoma: A Case Report
title Anti-PD-1 Therapy—A Potential Treatment for Myocardial Metastasis From Nasopharyngeal Carcinoma: A Case Report
title_full Anti-PD-1 Therapy—A Potential Treatment for Myocardial Metastasis From Nasopharyngeal Carcinoma: A Case Report
title_fullStr Anti-PD-1 Therapy—A Potential Treatment for Myocardial Metastasis From Nasopharyngeal Carcinoma: A Case Report
title_full_unstemmed Anti-PD-1 Therapy—A Potential Treatment for Myocardial Metastasis From Nasopharyngeal Carcinoma: A Case Report
title_short Anti-PD-1 Therapy—A Potential Treatment for Myocardial Metastasis From Nasopharyngeal Carcinoma: A Case Report
title_sort anti-pd-1 therapy—a potential treatment for myocardial metastasis from nasopharyngeal carcinoma: a case report
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602087/
https://www.ncbi.nlm.nih.gov/pubmed/34804001
http://dx.doi.org/10.3389/fimmu.2021.688682
work_keys_str_mv AT tangxiaowan antipd1therapyapotentialtreatmentformyocardialmetastasisfromnasopharyngealcarcinomaacasereport
AT zhouweijun antipd1therapyapotentialtreatmentformyocardialmetastasisfromnasopharyngealcarcinomaacasereport
AT huangdanjiang antipd1therapyapotentialtreatmentformyocardialmetastasisfromnasopharyngealcarcinomaacasereport
AT chenlili antipd1therapyapotentialtreatmentformyocardialmetastasisfromnasopharyngealcarcinomaacasereport
AT zhangguangwen antipd1therapyapotentialtreatmentformyocardialmetastasisfromnasopharyngealcarcinomaacasereport